Supernus Pharmaceuticals (NASDAQ:SUPN) and Assembly Biosciences (NASDAQ:ASMB) Head to Head Comparison

Assembly Biosciences (NASDAQ:ASMB) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership and valuation.

Insider and Institutional Ownership

19.9% of Assembly Biosciences shares are owned by institutional investors. 3.5% of Assembly Biosciences shares are owned by insiders. Comparatively, 0.7% of Supernus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Assembly Biosciences and Supernus Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$74.84 million	5.68	-$6.12 million	$1.02	20.47
Supernus Pharmaceuticals	$1.24 billion	2.64	$210.00 million	$3.58	7.75

Supernus Pharmaceuticals has higher revenue and earnings than Assembly Biosciences. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Assembly Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Assembly Biosciences and Supernus Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-0.06%	-0.02%	-0.02%
Supernus Pharmaceuticals	32.75%	-418.04%	42.96%

Analyst Recommendations

This is a breakdown of recent recommendations for Assembly Biosciences and Supernus Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	1	0	4	1	2.83
Supernus Pharmaceuticals	1	2	3	1	2.57

Assembly Biosciences presently has a consensus price target of $46.50, indicating a potential upside of 122.70%. Supernus Pharmaceuticals has a consensus price target of $60.20, indicating a potential upside of 117.02%. Given Assembly Biosciences’ stronger consensus rating and higher probable upside, research analysts clearly believe Assembly Biosciences is more favorable than Supernus Pharmaceuticals.

Risk and Volatility

Assembly Biosciences has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500.

Summary

Assembly Biosciences beats Supernus Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

About Assembly Biosciences

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.